Management of Peritoneal Metastases- Cytoreductive Surgery, HIPEC and Beyond (eBook, PDF)
85,59 €
inkl. MwSt.
Sofort per Download lieferbar
Management of Peritoneal Metastases- Cytoreductive Surgery, HIPEC and Beyond (eBook, PDF)
- Format: PDF
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei
bücher.de, um das eBook-Abo tolino select nutzen zu können.
Hier können Sie sich einloggen
Hier können Sie sich einloggen
Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
The widespread acceptance among the oncology community at large of cytoreductive surgery and HIPEC as a potentially curative treatment for peritoneal metastases has paved the way for innovative new therapies that could benefit a larger proportion of patients. Much has been and continues to be published on this subject.
This book provides comprehensive reviews on the various aspects of managing peritoneal metastases. The authors highlight essential practical issues that surgical oncologists encounter in their day-to-day practice, and try to before provide evidence based answers to address…mehr
- Geräte: PC
- ohne Kopierschutz
- eBook Hilfe
- Größe: 13.59MB
- Upload möglich
Andere Kunden interessierten sich auch für
- Treatment of Peritoneal Surface Malignancies (eBook, PDF)96,29 €
- Extreme Hepatic Surgery and Other Strategies (eBook, PDF)117,69 €
- Adenocarcinoma of the Esophagogastric Junction (eBook, PDF)106,99 €
- Peritoneale Tumoren und Metastasen (eBook, PDF)99,99 €
- Palliative Viszeralchirurgie (eBook, PDF)69,99 €
- Surgery for Pancreatic and Periampullary Cancer (eBook, PDF)96,29 €
- Personalized Treatment of Breast Cancer (eBook, PDF)149,79 €
-
-
-
The widespread acceptance among the oncology community at large of cytoreductive surgery and HIPEC as a potentially curative treatment for peritoneal metastases has paved the way for innovative new therapies that could benefit a larger proportion of patients. Much has been and continues to be published on this subject.
This book provides comprehensive reviews on the various aspects of managing peritoneal metastases. The authors highlight essential practical issues that surgical oncologists encounter in their day-to-day practice, and try to before provide evidence based answers to address them. All chapters were written and/or reviewed by leading experts in this field.
This book provides comprehensive reviews on the various aspects of managing peritoneal metastases. The authors highlight essential practical issues that surgical oncologists encounter in their day-to-day practice, and try to before provide evidence based answers to address them. All chapters were written and/or reviewed by leading experts in this field.
Produktdetails
- Produktdetails
- Verlag: Springer Singapore
- Erscheinungstermin: 2. April 2018
- Englisch
- ISBN-13: 9789811070532
- Artikelnr.: 52941162
- Verlag: Springer Singapore
- Erscheinungstermin: 2. April 2018
- Englisch
- ISBN-13: 9789811070532
- Artikelnr.: 52941162
''Dr. Aditi Bhatt is a Surgical oncologist specializing in the management of peritoneal surface malignancies. She has done her surgical oncology training from the Gujarat Cancer Research Institute in Ahmedabad, India and has further pursued a fellowship in peritoneal surface malignancies at Institut Gustave Roussy, Paris, France. She has been pursuing peritoneal surface oncology as a speciality for seven years. She was associate editor with Dr. Paul H. Sugarbaker for the special issue of the Indian Journal of Surgical Oncology on peritoneal surface malignancies in 2016. Dr. Aditi is currently involved in developing a robust system for collection and publication of Indian data pertaining to the management of peritoneal metastases and conducting multi-institutional studies. Here specific areas of interest are pseudomyoma peritonei and other rare peritoneal tumors and ovarian cancer.'
Evolving role of CRS and HIPEC: Current Indications, prevention and early treatment of peritoneal metastases.- Cytoreductive surgery: Patient selection, surgical techniques, and laparoscopic CRS.- HIPEC: Methodology, comparison of techniques, drug regimens. Is there a need for standardization?.- EPIC: Current role and future perspective.- Management of complications of CRS and HIPEC.- Imaging for PSM: Utility of MRI and PET CT.- Clinical trials in CRS and HIPEC: Ongoing trials and future directives.- Rare peritoneal tumors: Indications for CRS and HIPEC.- Management of recurrent ovarian cancer.- IP chemotherapy in the management of colorectal cancer.- PMP and appendiceal tumors: Classification systems and pitfalls, biomarkers, current treatment standards, and role of systemic therapy.- Malignant peritoneal mesothelioma.- PIPAC for the management of peritoneal metastases.- Quality of life issues in patients after CRS and HIPEC.- Palliative treatment options for patients with unresectable peritoneal metastases.- Registries and collaborative groups in peritoneal surface oncology.
Evolving role of CRS and HIPEC: Current Indications, prevention and early treatment of peritoneal metastases.- Cytoreductive surgery: Patient selection, surgical techniques, and laparoscopic CRS.- HIPEC: Methodology, comparison of techniques, drug regimens. Is there a need for standardization?.- EPIC: Current role and future perspective.- Management of complications of CRS and HIPEC.- Imaging for PSM: Utility of MRI and PET CT.- Clinical trials in CRS and HIPEC: Ongoing trials and future directives.- Rare peritoneal tumors: Indications for CRS and HIPEC.- Management of recurrent ovarian cancer.- IP chemotherapy in the management of colorectal cancer.- PMP and appendiceal tumors: Classification systems and pitfalls, biomarkers, current treatment standards, and role of systemic therapy.- Malignant peritoneal mesothelioma.- PIPAC for the management of peritoneal metastases.- Quality of life issues in patients after CRS and HIPEC.- Palliative treatment options for patients with unresectable peritoneal metastases.- Registries and collaborative groups in peritoneal surface oncology.
Evolving role of CRS and HIPEC: Current Indications, prevention and early treatment of peritoneal metastases.- Cytoreductive surgery: Patient selection, surgical techniques, and laparoscopic CRS.- HIPEC: Methodology, comparison of techniques, drug regimens. Is there a need for standardization?.- EPIC: Current role and future perspective.- Management of complications of CRS and HIPEC.- Imaging for PSM: Utility of MRI and PET CT.- Clinical trials in CRS and HIPEC: Ongoing trials and future directives.- Rare peritoneal tumors: Indications for CRS and HIPEC.- Management of recurrent ovarian cancer.- IP chemotherapy in the management of colorectal cancer.- PMP and appendiceal tumors: Classification systems and pitfalls, biomarkers, current treatment standards, and role of systemic therapy.- Malignant peritoneal mesothelioma.- PIPAC for the management of peritoneal metastases.- Quality of life issues in patients after CRS and HIPEC.- Palliative treatment options for patients with unresectable peritoneal metastases.- Registries and collaborative groups in peritoneal surface oncology.
Evolving role of CRS and HIPEC: Current Indications, prevention and early treatment of peritoneal metastases.- Cytoreductive surgery: Patient selection, surgical techniques, and laparoscopic CRS.- HIPEC: Methodology, comparison of techniques, drug regimens. Is there a need for standardization?.- EPIC: Current role and future perspective.- Management of complications of CRS and HIPEC.- Imaging for PSM: Utility of MRI and PET CT.- Clinical trials in CRS and HIPEC: Ongoing trials and future directives.- Rare peritoneal tumors: Indications for CRS and HIPEC.- Management of recurrent ovarian cancer.- IP chemotherapy in the management of colorectal cancer.- PMP and appendiceal tumors: Classification systems and pitfalls, biomarkers, current treatment standards, and role of systemic therapy.- Malignant peritoneal mesothelioma.- PIPAC for the management of peritoneal metastases.- Quality of life issues in patients after CRS and HIPEC.- Palliative treatment options for patients with unresectable peritoneal metastases.- Registries and collaborative groups in peritoneal surface oncology.